YOLFTbeta
Absci Corp

Absci Corp

ABSI · NASDAQ · Healthcare / Biotechnology

8.45USD-0.69 (-7.50%)

Price History

Full chart

Market Stats

Previous Close9.14
Open9.37
Day Range8.32 – 9.40
52-Week Range2.24 – 12.06
Volume5.47M
Market Cap1.78B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.84
Dividend Yield0.00%
Beta2.44
50-Day Avg8.74
200-Day Avg5.66

About

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Sean McClain
  • Employees140
  • Headquarters18105 SE Mill Plain Boulevard, Vancouver, WA, United States, 98683, USA
  • Websitehttps://www.absci.com

Leadership

  • Mr. Sean McClainFounder, CEO, President & Director · b. 1990
  • Dr. Zachariah Jonasson Ph.D.Chief Business Officer & CFO · b. 1973
  • Mr. Todd Bedrick CPASenior VP & Chief Accounting Officer
  • Mr. Alexander Khan CPACVP of Finance & Head of Investor Relations
  • Ms. Shelby Walker J.D.Chief Legal Officer · b. 1975
  • Ms. Jeanne Schreuder M.B.A., SPHRSenior Vice President of People & Experience
  • Mr. Wen ShaChief of Staff
  • Dr. Christine Lemke D.V.M., M.B.A., Ph.D.Senior Vice President of Portfolio & Growth Strategy
  • Dr. Ransi Somaratne FACC, M.B.A., M.D.Chief Medical Officer · b. 1966
  • Dr. Moetaz B. Albizem M.D.Senior Vice President of Clinical Operations

Financials

Income Statement

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue2.06M4.78M4.78M5.75M5.72M4.53M2.80M
Growth (%)-+132.04%+0.04%+20.18%-0.50%-20.71%-38.24%
Cost of Revenue4.31M11.45M44.59M58.91M47.57M62.46M11.74M
Gross Profit2.06M-6.67M-39.80M-53.16M-41.85M-57.92M-8.94M
Gross Margin100.00%-139.50%-832.37%-925.02%-731.88%-1277.57%-319.36%
Operating Expense8.32M6.63M35.43M53.59M73.67M50.96M115.78M
Operating Income-6.26M-13.30M-75.24M-106.75M-115.52M-108.89M-124.72M
Operating Margin-304.13%-278.26%-1573.36%-1857.49%-2020.20%-2401.59%-4454.21%
EBITDA-5.83M-12.59M-67.68M-91.36M-79.68M-94.10M-103.16M
EBITDA Margin-282.77%-263.35%-1415.39%-1589.63%-1393.51%-2075.41%-3684.39%
Net Income-6.58M-14.35M-100.96M-104.90M-110.57M-103.11M-115.18M
Net Income Margin-319.61%-300.27%-2111.25%-1825.37%-1933.65%-2274.06%-4113.68%
R&D4.31M11.45M44.59M58.91M48.07M63.86M81.42M
R&D as % of Total Revenue209.27%239.50%932.37%1025.02%840.63%1408.45%2907.79%
Interest Expense268.00K634.00K3.43M972.00K1.01M565.00K209.00K
Interest Expense % of Total Revenue13.01%13.26%71.77%16.91%17.66%12.46%7.46%

Balance Sheet

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets19.47M88.57M426.19M321.01M217.30M213.61M216.30M
Total Liabilities60.63M21.56M60.09M46.59M41.12M34.48M26.85M
Total Equity-41.16M67.00M366.11M274.41M176.18M179.13M189.45M
Cash13.09M69.87M252.57M59.95M72.36M41.21M20.02M
Total Debt6.02M14.50M20.01M22.98M15.88M10.11M5.30M
Net Debt-7.07M-55.37M-232.56M-36.97M-56.48M-31.11M-14.72M

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-6.03M-10.97M-60.60M-81.34M-64.64M-72.40M-92.92M
Investing Cash Flow-1.09M-2.17M-67.38M-126.98M81.94M-41.58M-50.16M
Financing Cash Flow12.71M70.97M336.19M5.24M-4.48M82.53M105.95M
Capital Expenditure1.10M2.18M38.05M16.18M860.00K404.00K1.11M
Free Cash Flow-7.13M-13.15M-98.64M-97.51M-65.50M-72.81M-94.03M
FCF to OCF118.20%119.88%162.79%119.89%101.33%100.56%101.19%

Earnings

Report DateMar 31, 2020Mar 31, 2021Jun 2, 2021Sep 7, 2021Nov 9, 2021Mar 22, 2022May 11, 2022Aug 11, 2022Nov 9, 2022Mar 30, 2023May 15, 2023Aug 14, 2023Nov 14, 2023Mar 21, 2024May 14, 2024Aug 14, 2024Nov 12, 2024Mar 19, 2025May 13, 2025Aug 12, 2025Nov 12, 2025Mar 24, 2026May 7, 2026Aug 11, 2026Nov 11, 2026
EPS Estimate0.000.000.00-0.85-0.17-0.25-0.28-0.31-0.28-0.25-0.24-0.24-0.22-0.25-0.20-0.18-0.19-0.22-0.22-0.21-0.21-0.18-0.20-0.20-0.15
EPS Actual-0.91-0.70-0.18-2.39-0.33-0.28-0.33-0.32-0.30-0.21-0.26-0.22-0.24-0.25-0.22-0.22-0.24-0.25-0.21-0.24-0.20-0.23-0.19-0.21-
Surprise----181.18%-94.12%-12.00%-17.86%-3.23%-7.14%16.00%-8.33%8.33%-9.09%0.00%-10.00%-22.22%-26.32%-11.71%4.55%-14.29%4.76%-27.78%5.00%-5.00%-
Timing---Pre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hours-

Key Statistics & Ratios

Market Cap1.78B
Enterprise Value1.48B
Trailing P/E0.00
Forward P/E0.00
Price / Sales1137.31
Price / Book6.79
EPS-0.84
Book Value1.44
Revenue (TTM)1.56M
Gross Profit (TTM)-84.23M
EBITDA-119.51M
Profit Margin0.00%
Operating Margin-10741.51%
Return on Equity-57.72%
Return on Assets-34.10%
Shares Outstanding171.61M
Shares Float163.79M
Beta2.44
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 9 analystsTarget 14.40
  • Strong Buy
    5
  • Buy
    4

Ownership Breakdown

Institutions
87.26%
Insiders
11.84%
Retail / Other
0.90%

Top Institutional Holders

  • FMR Inc
    22.55M13.14%
  • ARK Investment Management LLC
    13.73M8.00%
  • BlackRock Inc
    11.26M6.56%
  • State Street Corp
    7.32M4.27%
  • Redmile Group, LLC
    6.74M3.93%
  • Vanguard Capital Management, LLC
    5.89M3.43%
  • Advanced Micro Devices Inc
    5.71M3.33%
  • Adage Capital Partners Gp LLC
    5.70M3.32%
  • Two Sigma Investments LLC
    5.49M3.20%
  • D. E. Shaw & Co LP
    5.24M3.05%
  • Geode Capital Management, LLC
    3.34M1.95%
  • Woodline Partners LP
    3.30M1.92%
  • Ameriprise Financial Inc
    3.18M1.85%

Top Fund Holders

  • ARK Genomic Revolution ETF
    10.90M6.35%
  • Fidelity Growth Company Fund
    7.90M4.61%
  • State Street® SPDR® S&P® Biotech ETF
    5.46M3.18%
  • Vanguard MStar Total Stk Mkt Idx Invest
    4.46M2.60%
  • iShares Russell 2000 ETF
    3.53M2.06%
  • ARK Venture D
    3.01M1.76%
  • Fidelity Growth Company K6
    2.47M1.44%